On December 26, 2024, in San Diego, Viracta Therapeutics, Inc. (Nasdaq: VIRX), a company specializing in precision oncology for virus-associated cancers globally, revealed the initiation of a strategic review by its Board of Directors. This process will involve exploring diverse strategic options for the company's future direction.